Inovio Pharmaceuticals Inc (INO) News & EventsINOInovio Pharmaceuticals Inc

INOVIO Pharmaceuticals Secures $80.4 Million Judgment

INOVIO Pharmaceuticals announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI and GeneOne Life Science in the case captioned INOVIO Pharmaceuticals, Inc. v. VGXI, Inc. and GeneOne Life Science, Inc., No. 2020-06554, in the Court of Common Pleas of Montgomery County, Pennsylvania. The Court awarded INOVIO $61,750,789 in compensatory damages and $18,665,312 in fees and costs. The Court also entered judgment against defendants on their counterclaims. INOVIO filed the case on June 3, 2020, when defendants breached the parties' Supply Agreement by refusing to honor their technology transfer obligations to enable scalable manufacturing of DNA plasmids. Defendants' financial condition will likely impair INOVIO's ability to collect some or all of the judgment. INOVIO intends to use every reasonable effort to recover the damages awarded by this judgment. Cooley and FBT Gibbons served as trial counsel for INOVIO.

Significant Increases in Indicative Borrow Rates for Liquid Options

Latest data shows the largest indicative borrow rate increases among liquid option names include: Tradr 2X Short NBIS Daily ETF (NBIZ) 54.64% +3.60, T-REX 2X LONG MSTR DAILY TARGET (MSTU) 27.33% +2.11, Defiance Daily Target 2x Long OKLO ETF (OKLL) 59.16% +1.80, GraniteShares 2x Long INTC Daily ETF (INTW) 8.39% +0.91, GoPro (GPRO) 1.79% +0.83, US Global Jets ETF (JETS) 6.70% +0.77, GRANITESHARES 2X LONG AMD DAILY ETF (AMDL) 10.10% +0.63, Inovio (INO) 2.89% +0.58, Hesai Group (HSAI) 3.54% +0.48, and Defiance Daily Target 2X Long RKLB ETF (RKLX) 15.76% +0.40.

INOVIO Estimates Cash Balance Supports Operations into Late Q1 2027

INOVIO estimates that current cash, cash equivalents and short-term investments balances of $36.7M - excluding net proceeds from the July 2026 offering of approximately $18.3M - will support operations into late 1Q27, through a potential launch of INO-3107, if approved. "As the FDA's review of our BLA for INO-3107 continues to advance, we are pleased to have held the informal clinical meeting with the FDA, where we presented the totality of data supporting INO-3107's safety and efficacy and highly differentiated approach in treating RRP, and our rationale for accelerated approval eligibility," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We are confident in INO-3107's potential to become the preferred product among patients, healthcare providers and payers, if approved, and are committed to ensuring that all patients have access to therapeutic options that work for them in reducing the need for surgery to control their disease. We look forward to the final stages of the review process and further advancing our commercial preparations."